ProfileGDS5678 / 1456432_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 47% 46% 47% 64% 45% 48% 50% 46% 45% 46% 46% 46% 46% 46% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.1634247
GSM967853U87-EV human glioblastoma xenograft - Control 23.0858146
GSM967854U87-EV human glioblastoma xenograft - Control 33.1029647
GSM967855U87-EV human glioblastoma xenograft - Control 43.8454564
GSM967856U87-EV human glioblastoma xenograft - Control 52.9904945
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.2311748
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.2831150
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.0669846
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.0263245
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.0488846
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.0781446
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.0531146
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.0951846
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.0874646